Elanco Animal Health Incorporated Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Elanco Animal Health Incorporated (ELAN) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $28.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2026-02-24
- 2025-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $28.00M.
- 2024-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $28.00M.
- 2023-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $50.00M.
- 2022-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $64.00M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2025-12-31 | $28.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | $28.00M 10-K · filed 2025-02-25 |
| 2023-12-31 | $50.00M 10-K · filed 2024-02-26 |
| 2022-12-31 | $64.00M 10-K · filed 2023-03-01 |
| 2021-12-31 | $82.00M 10-K · filed 2022-02-28 |
| 2020-12-31 | $97.20M 10-K · filed 2021-03-01 |
| 2020-09-30 | $101.10M 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |